HUE038265T2 - Köszvény és hiperurikémia kezelése - Google Patents

Köszvény és hiperurikémia kezelése

Info

Publication number
HUE038265T2
HUE038265T2 HUE11796324A HUE11796324A HUE038265T2 HU E038265 T2 HUE038265 T2 HU E038265T2 HU E11796324 A HUE11796324 A HU E11796324A HU E11796324 A HUE11796324 A HU E11796324A HU E038265 T2 HUE038265 T2 HU E038265T2
Authority
HU
Hungary
Prior art keywords
hyperuricemia
gout
treatment
Prior art date
Application number
HUE11796324A
Other languages
English (en)
Hungarian (hu)
Inventor
Jeffrey Miner
Barry Quart
Jean-Luc Girardet
Original Assignee
Ardea Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45348529&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUE038265(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ardea Biosciences Inc filed Critical Ardea Biosciences Inc
Publication of HUE038265T2 publication Critical patent/HUE038265T2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HUE11796324A 2010-06-15 2011-06-14 Köszvény és hiperurikémia kezelése HUE038265T2 (hu)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US35500410P 2010-06-15 2010-06-15
US41144910P 2010-11-08 2010-11-08
US201161430522P 2011-01-06 2011-01-06
US201161489420P 2011-05-24 2011-05-24

Publications (1)

Publication Number Publication Date
HUE038265T2 true HUE038265T2 (hu) 2018-10-29

Family

ID=45348529

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE11796324A HUE038265T2 (hu) 2010-06-15 2011-06-14 Köszvény és hiperurikémia kezelése

Country Status (19)

Country Link
US (3) US9216179B2 (OSRAM)
EP (1) EP2582683B1 (OSRAM)
JP (1) JP5964821B2 (OSRAM)
CA (1) CA2802407C (OSRAM)
CY (1) CY1120473T1 (OSRAM)
DK (1) DK2582683T3 (OSRAM)
ES (1) ES2670700T3 (OSRAM)
HR (1) HRP20180780T1 (OSRAM)
HU (1) HUE038265T2 (OSRAM)
LT (1) LT2582683T (OSRAM)
NO (1) NO2019008I1 (OSRAM)
PL (1) PL2582683T3 (OSRAM)
PT (1) PT2582683T (OSRAM)
RS (1) RS57275B1 (OSRAM)
SI (1) SI2582683T1 (OSRAM)
SM (1) SMT201800266T1 (OSRAM)
TR (1) TR201806828T4 (OSRAM)
WO (1) WO2011159732A1 (OSRAM)
ZA (1) ZA201300055B (OSRAM)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2794798C (en) 2010-03-30 2017-05-30 Ardea Biosciences, Inc. Treatment of gout
LT2582683T (lt) * 2010-06-15 2018-06-11 Ardea Biosciences, Inc. Podagros ir hiperuricemijos gydymas
PL2776028T3 (pl) * 2011-11-03 2019-03-29 Ardea Biosciences, Inc. 3,4-di-podstawiony związek pirydynowy, sposoby jego zastosowania i zawierające go kompozycje
AR091651A1 (es) 2012-07-03 2015-02-18 Ardea Biosciences Inc Elaboracion de acido 2-(5-bromo-4-(4-ciclopropilnaftalen-1-il)-4h-1,2,4-triazol-3-iltio)acetico
US8883857B2 (en) 2012-12-07 2014-11-11 Baylor College Of Medicine Small molecule xanthine oxidase inhibitors and methods of use
CN103613552A (zh) * 2013-12-02 2014-03-05 苏州晶云药物科技有限公司 2-(5-溴-4-(4-环丙基萘-1-基)-4h-1，2，4-三唑-3-基硫基)乙酸钠的新晶型及其制备方法
US9969701B2 (en) 2013-12-20 2018-05-15 Crystal Pharmatech Co., Ltd. Salts and co-crystals of lesinurad
CN103755651A (zh) * 2013-12-23 2014-04-30 苏州晶云药物科技有限公司 2-(5-溴-4-(4-环丙基萘-1-基)-4h-1，2，4-三唑-3-基硫基)乙酸的盐的新晶型及其制备方法
JP2015160847A (ja) * 2014-02-28 2015-09-07 ベイラー カレッジ オブ メディスンＢａｙｌｏｒ Ｃｏｌｌｅｇｅ Ｏｆ Ｍｅｄｉｃｉｎｅ 小分子のキサンチンオキシダーゼ阻害剤および使用方法
CN105622531A (zh) 2015-04-03 2016-06-01 南京明德新药研发股份有限公司 轴手性异构体及其制备方法和制药用途
WO2016203436A1 (en) * 2015-06-19 2016-12-22 Dr. Reddy's Laboratories Limited Amorphous and amorphous solid dispersion of lesinurad and their preparation
EP3112334A1 (en) 2015-06-29 2017-01-04 DPx Fine Chemicals Austria GmbH & CoKG Process for manufacturing 1-cyclopropyl-naphthalenes
CN108289848A (zh) * 2015-12-08 2018-07-17 阿迪亚生命科学公司 包含urat1的有效抑制剂的药物组合物
US12152347B2 (en) 2018-10-26 2024-11-26 The Procter & Gamble Company Sanitary tissue product rolls
CA3060193C (en) 2018-10-26 2023-05-09 The Procter & Gamble Company Paper towel rolls
CA3060185A1 (en) 2018-10-26 2020-04-26 The Procter & Gamble Company Sanitary tissue product rolls
CA3060180A1 (en) 2018-10-26 2020-04-26 The Procter & Gamble Company Sanitary tissue product rolls
EP4019048A4 (en) * 2019-08-21 2023-10-04 The University of Tokyo ABCC11 INHIBITOR
CN110824067B (zh) * 2019-12-11 2024-12-27 天津药物研究院有限公司 一种非布司他中基因毒性杂质的检测方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1698635B1 (en) 2003-12-26 2011-12-14 Kissei Pharmaceutical Co., Ltd. Benzimidazole derivatives and medical uses thereof
US20060189811A1 (en) 2004-07-23 2006-08-24 Fujiyakuhin Co., Ltd. Process for producing 1,2,4-triazole compound and intermediate therefor
EP2433633A1 (en) 2004-08-25 2012-03-28 Ardea Biosciences, Inc. Triazolyl alpha -mercaptoacetanildes as inhibitors of HIV reverse transcriptase
WO2007050087A1 (en) 2004-08-25 2007-05-03 Ardea Biosciences, Inc. N[S(4-aryl-triazol-3-yl)α -mercaptoacetyl]-p-amino benozoic acids AS HIV REVERSE TRANSCRIPTASE INHIBITORS
AU2008206231A1 (en) 2007-01-19 2008-07-24 Takeda Pharmaceuticals U.S.A., Inc. Methods for preventing or reducing the number of gout flares using xanthine oxidoreductase inhibitors and anti-inflammatory agents
MX2010005776A (es) 2007-11-27 2010-08-31 Ardea Biosciences Inc Nuevos compuestos y composiciones y metodos de uso.
US8173690B2 (en) * 2008-09-04 2012-05-08 Ardea Biosciences, Inc. Compounds, compositions and methods of using same for modulating uric acid levels
CN103819419B (zh) 2008-09-04 2016-12-07 亚德生化公司 调节尿酸含量的化合物、组合物及其使用方法
US8242154B2 (en) 2008-09-04 2012-08-14 Ardea Biosciences, Inc. Compounds, compositions and methods of using same for modulating uric acid levels
US20100160351A1 (en) 2008-12-19 2010-06-24 Nuon Therapeutics, Inc. Pharmaceutical compositions and methods for treating hyperuricemia and related disorders
CA2761335A1 (en) * 2009-05-20 2010-11-25 Ardea Biosciences, Inc. Compounds, compositions and methods for modulating uric acid levels
EP2266966A1 (en) 2009-06-11 2010-12-29 Chemo Ibérica, S.A. A process for the preparation of febuxostat
BR112012016795A2 (pt) 2010-01-08 2020-09-01 Ardea Biosciences Inc. formas polimórficas, cristalinas e de mesofase de 2-(5- bromo -4-(4-ciclopropilnaftalen-1-il)-4h-1,2,34-triazol-3iltio) acetato de sódio e seus usos
CA2794798C (en) * 2010-03-30 2017-05-30 Ardea Biosciences, Inc. Treatment of gout
LT2582683T (lt) * 2010-06-15 2018-06-11 Ardea Biosciences, Inc. Podagros ir hiperuricemijos gydymas
EP2588110B1 (en) * 2010-07-02 2018-10-17 University Health Network Methods of targeting pten mutant diseases and compositions therefor
CA2813555C (en) * 2010-10-15 2014-11-25 Ardea Biosciences, Inc. Methods for treating hyperuricemia and related diseases
ES2614914T3 (es) 2010-12-30 2017-06-02 Ardea Biosciences, Inc. Formas polimórficas de ácido 2-(5-bromo-4-(4-ciclopropilnaftalen-1-il)-4H-1,2,4-triazol-3-iltio)acético y usos de las mismas
LT2714669T (lt) 2011-05-24 2017-08-10 Ardea Biosciences, Inc. Hipertenzija ir hiperurikemija

Also Published As

Publication number Publication date
SI2582683T1 (en) 2018-07-31
CA2802407A1 (en) 2011-12-22
PL2582683T3 (pl) 2018-08-31
DK2582683T3 (en) 2018-06-06
ES2670700T3 (es) 2018-05-31
US20190015392A1 (en) 2019-01-17
EP2582683A1 (en) 2013-04-24
US9216179B2 (en) 2015-12-22
JP5964821B2 (ja) 2016-08-03
SMT201800266T1 (it) 2018-07-17
NO2019008I1 (no) 2019-02-19
TR201806828T4 (tr) 2018-06-21
HRP20180780T1 (hr) 2018-07-13
CY1120473T1 (el) 2019-07-10
WO2011159732A1 (en) 2011-12-22
PT2582683T (pt) 2018-05-25
EP2582683A4 (en) 2014-04-30
JP2013528650A (ja) 2013-07-11
LT2582683T (lt) 2018-06-11
US20130178484A1 (en) 2013-07-11
US20160143889A1 (en) 2016-05-26
CA2802407C (en) 2018-01-23
RS57275B1 (sr) 2018-08-31
ZA201300055B (en) 2018-05-30
EP2582683B1 (en) 2018-03-21

Similar Documents

Publication Publication Date Title
ZA201300055B (en) Treatment of gout and hyperuricemia
IL248530A0 (en) Biomarkers and treatment methods
ZA201304280B (en) Treatment of jak2-mediated conditions
GB2498121B (en) Treatment device and method of use
ZA201207973B (en) Treatment of gout
IL222227A0 (en) Pyrazol - 4 - heterocyclyl-carboxamide compounds and methods of use
EP2464227A4 (en) COMPOUNDS AND METHODS OF USE
EP2627331A4 (en) METHODS OF TREATING HYPERURICEMIA AND RELATED DISEASES
GB0915515D0 (en) Treatment of vasculoproliferative conditions
EP2574172A4 (en) MATERIALS AND METHOD FOR TREATING INFLAMMATION
IL265950A (en) Detection and treatment of leprosy
AP3480A (en) Phosphaplatins and their use for treatment of cancers
ZA201301936B (en) Methods and compositions for treatment of diabetes and dyslipidemia
IL256026B (en) Treatment methods
PL2575858T3 (pl) Sposoby leczenia zespołu nerczycowego
GB0908101D0 (en) Treatment of stress
ZA201207496B (en) Treatment of chicory
ZA201404738B (en) Treatment of type i and type ii diabetes
ZA201207497B (en) Treatment of chicory
EP2585103A4 (en) METHOD OF TREATMENT
ZA201301175B (en) Biomarkers and methods of treatment
GB0919985D0 (en) Treatment of grain
GB201014736D0 (en) Treatment of hepatitis C
GB201003917D0 (en) Method of treatment